Biologics

Cerapedics began its investigational device exemption clinical trial for its P-15L Peptide Enhanced Bone Graft.

The global spine biologics market is projected to grow at a 4.4 percent compound annual growth rate, from $226 billion in 2018 to $280 billion by 2023, according to a Market Data Forecast report.

Orthopedic company 206 Ortho secured a patent for a new biocompatible composite designed to repair load-bearing bone and resorb without leaving a trace.

Atlanta-based Emory Orthopaedics & Spine Center earned a $13 million grant from The Marcus Foundation for a multicenter clinical trial to evaluate stem cell treatments for osteoarthritis.

Bone Biologics completed $5.9 million of financing.

Bioventus entered into a definitive agreement to divest its bone morphogenetic protein development program to a new Viscogliosi Brothers company.

Ortho Regenerative Technologies is an orthopedic biotechnology company developing novel therapeutic tissue repair devices for sports medicine surgeries.

Here are 23 study developments in spine and orthopedic biologics for 2018 so far:

AlloSource is the world's largest processor of cellular bone allografts.

Aziyo Biologics agreed to provide its viable bone matrix product ViBone to medical device company SurGenTec for use with the GraftGun universal graft delivery system.